A phase I/II trial combining the HDAC inhibitor vorinostat with bevacizumab achieved an 18% objective response rate and a 6-month PFS of about 48% in metastatic ccRCC [43]. This evidence concerns the gene HDAC9 and nonpapillary renal cell carcinoma.